What does this research mean for the field?

Inhibitors of the platelet glycoprotein IIb/IIIa receptor have potential utility as conjunctive therapy for coronary artery thrombolysis. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

November 1, 1992

Inhibitors of the platelet glycoprotein IIb/IIIa receptor as conjunctive therapy for coronary artery thromboiysis

Key Points

Key points are not available for this paper at this time.

Abstract

From the Division of Hematology, State University of New York at Stony Brook, Health Sciences Center, Stony Brook, NY,

AIに質問

Bookmark

Cite This Study

Barry S. Coller (Sun,) studied this question.

synapsesocial.com/papers/6a1bf08d4ebd09f3dfa93b58 https://doi.org/https://doi.org/10.1097/00019501-199211000-00005

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The role of platelet glycoprotein IIb / IIIa inhibitors in current treatment of acute coronary syndrome2022 · 5 citations
2Glycoprotein IIb/IIIa Antagonists2003
3Platelet Glycoprotein IIb/IIIa Receptor Antagonists in Cardiovascular Disease1999 · 124 citations
4Platelet Glycoprotein IIb/IIIa Receptors in Cardiovascular Medicine1995 · 760 citations
5Assessing platelet function during treatment with glycoprotein IIb/IIIa antagonists2003 · 7 citations

AIに質問

Bookmark